J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027

What happened: Johnson & Johnson beat earnings estimates and said it aims to spin off its hip and knee unit by mid-2027. Key numbers: Pharmaceutical sales rose 7.7% to $16.76 billion. Medical technology division sales rose 2.5% to $8.6 billion. Why it matters: The slower growth in medical technology contrasts with the stronger pharmaceutical segment as J&J moves toward separating the hip and knee business.

Johnson & Johnson beat earnings estimates and said it aims to spin off its hip and knee unit by mid-2027.

The slower growth in medical technology contrasts with the stronger pharmaceutical segment as J&J moves toward separating the hip and knee business.